ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Vor Biopharma Inc

Vor Biopharma Inc (VOR)

2.37
0.16
(7.24%)
Closed March 29 04:00PM
2.33
-0.04
(-1.69%)
After Hours: 07:35PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.33
Bid
2.25
Ask
2.37
Volume
482,781
2.21 Day's Range 2.38
1.62 52 Week Range 5.80
Market Cap
Previous Close
2.21
Open
2.24
Last Trade
25
@
2.33
Last Trade Time
Financial Volume
$ 1,114,465
VWAP
2.3084
Average Volume (3m)
297,730
Shares Outstanding
67,805,687
Dividend Yield
-
PE Ratio
-1.73
Earnings Per Share (EPS)
-1.36
Revenue
-
Net Profit
-92.09M

About Vor Biopharma Inc

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Vor Biopharma Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker VOR. The last closing price for Vor Biopharma was $2.21. Over the last year, Vor Biopharma shares have traded in a share price range of $ 1.62 to $ 5.80.

Vor Biopharma currently has 67,805,687 shares outstanding. The market capitalization of Vor Biopharma is $159.34 million. Vor Biopharma has a price to earnings ratio (PE ratio) of -1.73.

VOR Latest News

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the...

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.4825.94594594591.852.381.84478482.02178008CS
40.167.37327188942.172.431.733475752.04097193CS
120.198.87850467292.143.13991.732977302.13652173CS
260.2210.42654028442.113.13991.622132952.11519518CS
52-3.41-59.40766550525.745.81.621842272.88625672CS
156-34.25-93.630399125236.5843.651.621467387.48657222CS
260-39.69-94.455021418442.0263.621.6215625711.0409226CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

Your Recent History

Delayed Upgrade Clock